United Therapeutics (UTHR) expanded its pulmonary fibrosis strategy at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026, detailing a multi-drug pipeline spanning approved and investigational therapies for idiopathic pulmonary fibrosis, progressive pulmonary fibrosis and pulmonary hypertension associated with COPD.
The company's near-term focus centers on nebulous Tyvaso for IPF, with a launch expected in mid-2025, and Tresmi, for which an NDA filing is planned by the end of 2024 for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Executives also pointed to later-stage assets, including phase III data for progressive pulmonary fibrosis anticipated in the second half of 2027, and the SUMMIT trial for PH-COPD, with a filing targeted for 2030 and a launch expected in the early 2030s.
Chief Executive Martine Rothblatt described the company's broader portfolio potential at $50 billion to $100 billion, with a base-case fibrosis pharma revenue estimate of $40 billion. Total addressable market for PH-COPD alone was estimated at approximately $60 billion. Last twelve months revenue stood at $3.15 billion, with a gross profit margin of 86%.
Clinical data presented underscored the competitive positioning of United Therapeutics' pipeline. Nebulized Tyvaso demonstrated an annual forced vital capacity decline of 40 to 50 ml in IPF trials, compared with 100 to 125 ml for Boehringer Ingelheim's JASCAYD and 200 to 250 ml in untreated patients. About 50% of patients achieved clinical improvement in status across trials for both ralinepag (YUTREPIA) and Tyvaso.
The patient populations underlying these indications are substantial. The U.S. IPF market comprises roughly 100,000 patients, while progressive pulmonary fibrosis affects an estimated 300,000 — approximately three times the IPF population. Combined IPF and PPF represent about 400,000 patients in the United States, with PH-COPD affecting between 400,000 and 800,000.
Commercial infrastructure is being scaled to support the pipeline expansion. The interstitial lung disease sales force doubled recently, and management intends to double it again every two to three years over the coming years, requiring at least 1,000 sales representatives to adequately cover the IPF and PPF markets.
Intellectual property protection for the company's fibrotic indications and ralinepag extends into the 2040s, providing a long commercial runway. United Therapeutics employs approximately 2,000 people and has 14 drugs in active development.
Shares closed at $502.70 on September 14, up 1.12% from $497.11, trading within a 52-week range of $396.12 to $609.35. Total return over the past year was 24%, with a beta of 0.56 and a P/E ratio of 17.97. Wall Street analyst price targets range from $515 to $725.
Also mentioned during the conference was Unituxin, which saves approximately 500 children annually, and existing portfolio products Remodulin, Orenitram and Tyvaso, alongside the phase III TETON-1 and TETON-2 IPF studies and the INCREASE study for PPF/ILD.
